Table 4. Adverse events related to sorafenib before and 2 months after discontinuation of sorafenib.
Before discontinuation | 2 months after discontinuation | ||||
---|---|---|---|---|---|
Adverse events | Test (n = 102) | Control (n = 55) | P | Control (n = 55) | P |
Hand-foot skin reaction | 72(70.6) | 36(64.5) | 0.789 | 8(14.5) | <0.001 |
Grade 1–2 | 61(59.8) | 31(56.4) | 8(14.5) | ||
Grade 3–4 | 11(10.8) | 5(9.1) | 0 | ||
Diarrhoea | 52(50.9) | 27(49.1) | 0.853 | 0 | <0.001 |
Grade 1–2 | 44(43.1) | 24(43.6) | 0 | ||
Grade 3–4 | 8(7.8) | 3(5.5) | 0 | ||
Hypertension | 4(3.9) | 2(3.6) | 0.309 | 0 | 0.361 |
Grade 1–2 | 4(3.9) | 1(1.8) | 0 | ||
Grade 3–4 | 0 | 1(1.8) | 0 | ||
Alopecia | 0.345 | 0.004 | |||
Grade 1–2 | 39(38.2) | 24(43.6) | 10(18.2) | ||
Weight loss | 0.924 | 0.039 | |||
Grade 1–2 | 40(39.2) | 22(40) | 12(21.8) | ||
Fatigue | 0.797 | 0.002 | |||
Grade 1–2 | 35(34.3) | 20(36.4) | 6(10.9) |
Note- data are numbers of patients, data in parentheses are percentages.